Announcement • May 09
Akari Therapeutics, Plc has filed a Follow-on Equity Offering. Akari Therapeutics, Plc has filed a Follow-on Equity Offering.
Security Name: American Depositary Shares
Security Type: Depositary Receipt (Common Stock)
Securities Offered: 1,139,818
Price\Range: $6.58
Security Name: Series H Common Warrants
Security Type: Equity Warrant
Securities Offered: 1,139,818
Security Name: Series I Common Warrants
Security Type: Equity Warrant
Securities Offered: 1,139,818
Security Name: Pre-Funded Warrants
Security Type: Equity Warrant
Securities Offered: 1,139,818 New Risk • May 07
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 16% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$11m free cash flow). Share price has been highly volatile over the past 3 months (16% average weekly change). Earnings are forecast to decline by an average of 23% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (57% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (US$6.59m market cap). Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (US$29m net loss in 3 years). Announcement • Apr 29
Akari Therapeutics, Plc Secures Australian Patent Approval for Proprietary PH1 RNA Splicing Modulator ADC Payload Akari Therapeutics, Plc announced the acceptance of an Australian patent covering its core payload technology, and further expanding protection of its proprietary ADC platform. The accepted patent (Application No. 2024201765), titled “Thailanstatin Analogs,” includes composition-of-matter claims covering proprietary analogs of Thailanstatin designed for use as cytotoxic ADC therapeutics. This patent contains broad claims covering the use of these proprietary splicing payloads with ADC linkers and may be used to target different proteins on the cancer cell. Akari’s growing pipeline of novel ADCs including AKTX-101 (targeting TROP2 directed) and AKTX-102 (targeting CEACAM5) all use the PH1 payload that is built around this novel IP. Targeting RNA splicing biology has the potential to be a highly effective and differentiated strategy to attack cancer tumors in multiple ways by eliminating vital proteins needed for cancer cell survival, as well as uniquely activating the immune system to drive durable efficacy. This Australian patent approval builds on Akari’s expanding global intellectual property portfolio, which includes issued patents in the United States, China, India, Japan, Israel, and Mexico, further strengthening protection of its proprietary PH1 payload platform and reinforcing the Company’s strategy to establish broad, global composition-of-matter coverage. Akari’s lead program, AKTX-101, a TROP2-targeting ADC powered by its proprietary PH1 payload, is currently in IND-enabling studies with a targeted Phase 1 first-in-human clinical trial expected in late 2026/early 2027. This enables Akari to continue to advance its novel ADC into a rapidly evolving TROP2 ADC class expected to reach ~$12B by 2033. This patent approval further strengthens Akari’s intellectual property across payload chemistry, ADC architecture, and therapeutic applications, supporting the Company’s strategy to advance a durable and differentiated platform for next-generation ADC development. The PH1 payload has also been demonstrated to be very active against cancer cells with key oncogenic drivers such as KRAS, BRAF, ARV7, FGFR3 fusions, and others. The Company has initiated IND enabling studies for AKTX-101 with a goal of starting its First-In-Human trial by late 2026/early 2027. Akari is also developing AKTX-102, an ADC candidate targeting CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a well-validated tumor antigen broadly expressed across multiple solid tumors. AKTX-102 is designed to leverage Akari’s proprietary PH1 spliceosome-modulating payload and a novel antibody construct to enable differentiated tumor cell killing and immune activation. 
